RAM
BDTX icon

Redmond Asset Management’s Black Diamond Therapeutics BDTX Stock Holding History

Redmond Asset Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,978
Closed -$27K – 169
2022
Q3 		$27K Sell
15,978
-29
-0.2% -$89 0.01% 169
2022
Q2 		$39K Hold
16,007
– – 0.01% 184
2022
Q1 		$44K Buy
16,007
+45
+0.3% +$164 0.01% 188
2021
Q4 		$85K Buy
15,962
+329
+2% +$2.3K 0.02% 195
2021
Q3 		$132K Hold
15,633
– – 0.04% 185
2021
Q2 		$191K Hold
15,633
– – 0.06% 185
2021
Q1 		$379K Buy
+15,633
New +$422K 0.12% 166

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Redmond Asset Management's BDTX Position: Q4 2022 in Review

Redmond Asset Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2022, closing a stake of 15,978 shares — an estimated $27K sold.

Redmond Asset Management first reported a position in BDTX in Q1 2021 and held it in 7 quarters. The position peaked at $379K in Q1 2021. 59 funds tracked by Wall St. Rank hold BDTX as of Q4 2022.

  • Redmond Asset Management reported no remaining Black Diamond Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Redmond Asset Management sold 15,978 Black Diamond Therapeutics shares in Q4 2022, an estimated $27K.
  • Redmond Asset Management first reported a position in Black Diamond Therapeutics in Q1 2021 and held it in 7 quarters.
  • Redmond Asset Management's Black Diamond Therapeutics position peaked at $379K in Q1 2021.
  • 59 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2022.

Based on Redmond Asset Management's 13F filing for Q4 2022, filed 6 Feb 2023.